The PI3K inhibitor, taselisib (GDC-0032), has enhanced potency in PIK3CA mutant models through a unique mechanism of action

被引：4
|
作者：
Edgar, Kyle A.
Song, Kyung
Schmidt, Stephen
Kirkpatrick, Don
Phu, Lilian
Nannini, Michelle
Hong, Rebecca
Cheng, Eric
Young, Amy
Sampath, Deepak
Friedman, Lori S.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-370
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
370
引用
收藏
页数：3
相关论文
共 50 条
  • [31] SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors
    Baselga, Jose
    Cortes, Javier
    DeLaurentils, Michelino
    Dent, Susan
    Dieras, Veronique
    Harbeck, Nadia
    Hsu, Jerry Y.
    Jin, Huan
    Schimmoller, Frauke
    Wilson, Timothy R.
    Im, Young-Hyuck
    Jacot, William
    Krop, Ian E.
    Verma, Sunil
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers
    Jhaveri, Komal
    Chang, Matthew T.
    Juric, Dejan
    Saura, Cristina
    Gambardella, Valentina
    Melnyk, Anton
    Patel, Manish R.
    Ribrag, Vincent
    Ma, Cynthia X.
    Aljumaily, Raid
    Bedard, Philippe L.
    Sachdev, Jasgit C.
    Dunn, Lara
    Won, Helen
    Bond, John
    Jones, Surai
    Savage, Heidi M.
    Scaltriti, Maurizio
    Wilson, Timothy R.
    Wei, Michael C.
    Hyman, David M.
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (02) : 447 - 459
  • [33] Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway
    Zhihang Chen
    Chun Wang
    Hao Dong
    Xing Wang
    Feng Gao
    Sen Zhang
    Xiaolong Zhang
    [J]. Molecular Medicine, 2020, 26
  • [34] Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway
    Chen, Zhihang
    Wang, Chun
    Dong, Hao
    Wang, Xing
    Gao, Feng
    Zhang, Sen
    Zhang, Xiaolong
    [J]. MOLECULAR MEDICINE, 2020, 26 (01)
  • [35] GDC-0032, A Novel p110α Inhibitor, Specifically Radiosensitizes Head and Neck Squamous Cell Carcinomas Harboring Activating PIK3CA Alterations
    Zumsteg, Z. S.
    Morse, N.
    Higginson, D.
    Gupta, G.
    Morris, L.
    Ganly, I.
    Grandis, J.
    Lee, N. Y.
    Powell, S. N.
    Scaltriti, M.
    Baselga, J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S37 - S37
  • [36] Major structure-based discoveries en route to clinical PI3K-inhibitor GDC-0032
    Staben, Steven T.
    Heffron, Timothy P.
    Olivero, Alan G.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
  • [37] SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors.
    Baselga, Jose
    Cortes, Javier
    De Laurentiis, Michele
    Dieras, Veronique
    Harbeck, Nadia
    Hsu, Jerry Y.
    Ng, Vivian
    Schimmoller, Frauke
    Wilson, Timothy R.
    Im, Young-Hyuck
    Jacot, William
    Krop, Ian E.
    Verma, Sunil
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [38] Differential response to a dual PI3K/mTOR inhibitor in PIK3CA mutant urothelial cancer patient derived xenografts
    Elbanna, May F.
    Ciamporcero, Eric
    Adelaiye, Remi
    Orillion, Ashley
    Chintala, Sreenivasulu
    Pili, Roberto
    [J]. CANCER RESEARCH, 2016, 76
  • [39] Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer
    Wang, Dong
    Wang, Min
    Jiang, Nan
    Zhang, Yuan
    Bian, Xing
    Wang, Xiaoqing
    Roberts, Thomas M.
    Zhao, Jean J.
    Liu, Pixu
    Cheng, Hailing
    [J]. ONCOTARGET, 2016, 7 (11) : 13153 - 13166
  • [40] CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
    Vora, Sadhna R.
    Juric, Dejan
    Kim, Nayoon
    Mino-Kenudson, Mari
    Huynh, Tiffany
    Costa, Carlotta
    Lockerman, Elizabeth L.
    Pollack, Sarah F.
    Liu, Manway
    Li, Xiaoyan
    Lehar, Joseph
    Wiesmann, Marion
    Wartmann, Markus
    Chen, Yan
    Cao, Z. Alexander
    Pinzon-Ortiz, Maria
    Kim, Sunkyu
    Schlegel, Robert
    Huang, Alan
    Engelman, Jeffrey A.
    [J]. CANCER CELL, 2014, 26 (01) : 136 - 149
12345